Launched in 2014 as a global network of patient-focused communities, StudyKIK and its technology platform has demonstrated improved quality and accelerated enrollment timelines in certain clinical trials by up to 94% and reduced enrollment start-up times by up to 75%. In addition, StudyKIK provides eConsent, Telemedicine video calling, Phone Pre-Qualifications, and Patient Retention application solutions. The company manages over 1,000 indication-specific patient community groups and has enrolled more than 5,400 protocols supporting over 3,800 research sites across the globe. The platform encompasses more than 6 million patients through social media, speeding access to patients who traditionally would not have participated in clinical trials.
Aligned to Syneos Health’s patient, site and community strategic focus, StudyKIK adds new scale and capabilities to improve the patient journey while optimizing data science and behavioral insights to support commercialization for products. This acquisition further expands Syneos Health’s portfolio of patient-direct, technology-enabled solutions complementing the recent acquisition of
“StudyKIK’s patient-first focus, combined with their innovative enterprise platform, helps to advance our goal of bringing best-of-breed insights and technology-enabled solutions to biopharma customers, sites and patients,” said
The acquisition of StudyKIK is also strategic to growing the
“StudyKIK’s mission has always focused on making a difference in the world by bringing new treatments to people faster through education and innovative, industry-leading tools and services that make access to clinical trials easier,” said
About StudyKIK
StudyKIK is a patient recruitment and retention technology company that was founded on building patient communities to increase awareness for clinical trials. Servicing over 3,600 research sites, StudyKIK supports patient recruitment, patient retention, eConsent Solutions, Telemedicine Video Calling, and study companion mobile applications to expedite clinical trials. They have addressed the clinical trial patient recruitment and retention problem by building the technology solutions needed for research sites and pharmaceutical companies to access, manage, and communicate with high-quality patients in real-time.
About
To learn more about how we are Shortening the Distance From Lab to Life®, visit syneoshealth.com or subscribe to our podcast.
Investor Relations Contact: Senior Vice President, Investor Relations +1 919 745 2745 Investor.Relations@syneoshealth.com | Press/Media Contact: Executive Director, +1 908 763 3428 gary.gatyas@syneoshealth.com | |
Source:
2021 GlobeNewswire, Inc., source